MNKD · MannKind Corporation
$3.19
-0.31% last session
End-of-day data · close of 2026-10-23
Market cap
$1B
Enterprise value
$1B
Trailing P/E
—
Forward P/E
23.6
Dividend yield
0.0%
Beta
1.08
Avg volume
4M
Employees
1K
Daily Change %
-0.31%
5 Days Change
5.26%
10 Days Change
4.92%
30 Days Change
-4.19%
60 Days Change
-21.38%
Month to Day Change
-18.99%
Year to Day Change
-43.56%
Analyst Outlook
Analyst estimates change daily — follow the shifts on the Estimate Trends page.
Technical Analysis
Analyst sentiment over time — MNKD
Rec Mean (blue, left — higher = more bullish) vs. price targets (right).
Investment Bank Ratings as of 2026-10-20
Latest call per bank · past 12 months
Wells Fargo
Overweight$13.00
+307.5% vs priceRBC Capital
Sector Perform$4.75
+48.9% vs priceRecent rating actions
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-10-20 | Cantor Fitzgerald | Reiterates | Overweight | $8.00 |
| 2026-10-19 | Chardan Capital | Initiates | Buy | $0.00 → $10.00 |
| 2026-10-07 | Truist Securities | Maintains | Buy | $6.00 → $5.00 |
| 2026-09-11 | Cantor Fitzgerald | Reiterates | Overweight | $8.00 |
| 2026-08-06 | Wells Fargo | Maintains | Overweight | $14.00 → $13.00 |
| 2026-07-30 | Wells Fargo | Maintains | Overweight | $11.00 → $14.00 |
| 2026-05-07 | RBC Capital | Maintains | Sector Perform | $3.50 → $4.75 |
| 2026-05-07 | Wells Fargo | Maintains | Overweight | $8.00 → $10.00 |
Ratings and price targets are the published opinions of the issuing banks, compiled from Yahoo Finance rating actions — not investment advice.
Signal Summary as of 2026-10-23
- neutral: RSI (14): RSI is 43 — neutral momentum, neither overbought nor oversold.
- bearish: Price vs 50-day MA: Trading 12.6% below the 50-day MA ($3.65).
- bearish: Price vs 200-day MA: Trading 15.8% below the 200-day MA ($3.79).
- bearish: MA cross: The 50-day MA sits below the 200-day MA (death-cross regime) — the longer-term trend points down.
- bullish: MACD (12,26,9): MACD histogram is positive (+0.00) — short-term momentum is improving.
- neutral: 52-week range: Price sits between the 52-week low ($2.28) and high ($6.21).
MNKD Price Chart
Loading chart for MNKD…
Fundamentals
About MannKind Corporation
MannKind Corporation, a biopharmaceutical company, focuses on the provision of various solutions for transforming chronic disease care. It develops and commercializes treatments that address various unmet medical needs, including diabetes, pulmonary hypertension, and fluid overload in heart failure and chronic kidney disease. The company's commercial products include Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes; Furoscix, a formulation of furosemide injection to treat edema in pediatric patients and adult patients with chronic heart failure or chronic kidney disease; and V-Go, a mechanical basal-bolus insulin delivery system, which provides continuous subcutaneous infusion of insulin in adults that require insulin. It also developed Tyvaso DPI inhalation powder for the treatment of pulmonary arterial hypertension, as well as for the treatment of pulmonary hypertension associated with interstitial lung disease. The company's pipeline of treatments for orphan lung diseases include MNKD-201, a dry-powder formulation of nintedanib for the treatment of idiopathic pulmonary fibrosis and MNKD-701 that focuses on bumetanide. It has collaboration and license agreement with United Therapeutics Corporation; collaboration agreement with Thirona Bio, Inc. to evaluate the therapeutic for the treatment of pulmonary fibrosis; and licensing and collaboration agreement with Rose Pharma Inc. to develop ROSE-010 Technosphere for weight management. MannKind Corporation was incorporated in 1991 and is headquartered in Danbury, Connecticut.
More in Biotechnology
VRTX
Vertex Pharmaceuticals Incorpor
$133B 18.1% YTD
REGN
Regeneron Pharmaceuticals, Inc.
$83B 6.5% YTD
MRNA
Moderna, Inc.
$80B 587.1% YTD
ARGX
argenx SE
$55B 4.1% YTD
ONC
BeOne Medicines Ltd.
$43B 25.8% YTD
RVMD
Revolution Medicines, Inc.
$40B 135.6% YTD
RPRX
Royalty Pharma plc
$37B 67.3% YTD
ALNY
Alnylam Pharmaceuticals, Inc.
$30B -42.8% YTD
Data is sourced from end-of-day snapshots and refreshed daily before the US market open — nothing on this page is real-time. Figures can contain vendor errors. This page is for information only and is not investment advice.